News

The average brokerage recommendation (ABR) for Intuitive Surgical (ISRG) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

FDA safety alerts and voluntary recalls tied to Intuitive Surgical stapler reloads have brought fresh regulatory focus to the da Vinci platform. The issues relate to certain da Vinci S and Si instruments and SureForm reloads, with complaints prompting added scrutiny from regulators. Investors have reacted, with NasdaqGS:ISRG down 26.9% year to date and 19.7% over the past year, and the stock last closing at $411.06. This mix of regulatory pressure and weaker recent returns is putting...

Mastercard, Seagate and Intuitive Surgical lead Zacks' featured reports as AI demand, payments growth and procedure expansion shape outlooks.

Recently, Zacks.com users have been paying close attention to Intuitive Surgical (ISRG). This makes it worthwhile to examine what the stock has in store.

Mastercard, Seagate and Intuitive Surgical headline new research reports, highlighting growth drivers, outlooks and key challenges shaping performance.

Is ISRG a good stock to buy? We came across a bullish thesis on Intuitive Surgical, Inc. on r/investing_discussion by Variant_Invest. In this article, we will summarize the bulls’ thesis on ISRG. Intuitive Surgical, Inc.’s share was trading at $412.02 as of June 10th. ISRG’s trailing and forward P/E were 50.06 and 39.68 respectively according to Yahoo […]

In the most recent trading session, Intuitive Surgical, Inc. (ISRG) closed at $426.61, indicating a +1.91% shift from the previous trading day.

Intuitive Surgical’s fair value estimate has been reset from US$611.82 to US$565.25, signaling a lower price target that analysts are now using in their models. This shift lines up with recent research that blends optimism about the company’s long term growth potential with caution around weaker medtech sentiment and a reset in sector valuations, leaving opinions on the stock’s risk reward profile divided. As you read on, you will see how this evolving narrative may shape how you track...

Intuitive Surgical (ISRG) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

ISRG lifts margins despite tariffs, using scale, cost cuts and da Vinci 5 adoption to offset inflation as 2026 cost pressures build.

Over the long term, the IHI ETF looks like a good turnaround story.

Medtronic wants a bite of the robotics-assisted surgery market, which could swell to over $63 billion over the next decade.

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.

If you are wondering whether Intuitive Surgical at around US$418.82 is starting to look attractively priced or still expensive, it helps to break the story into what the stock has done recently and how that lines up with its fundamentals. The share price is down 1.1% over the past week, 7.2% over the past month, and 25.5% year to date, although it is still up 34.7% over three years and 46.2% over five years. These mixed returns sit against an ongoing stream of interest in robotic assisted...

Intuitive Surgical (ISRG) is back in focus after promoting Taylor Patton to Chief Commercial and Marketing Officer. This leadership shift puts commercial execution, global scaling, and its surgical data and AI ambitions under the spotlight for investors. See our latest analysis for Intuitive Surgical. The stock has fallen 25.5% year to date on a share price basis and is down 25.0% over the past year on a total shareholder return basis, signaling fading momentum despite a 46.3% total...

These stocks are down more than 10% this year, and now could be a great time to buy them for the long haul.

The robotic-surgery leader has lost nearly a third of its value since January. Here's what's weighing on the stock.

Securing 510(k) authorization would position Medtronic to compete with Intuitive in major robotic surgery markets.

Although Becton, Dickinson and Company has underperformed its sector peers recently, analysts remain moderately optimistic about the stock’s prospects.

Intuitive Surgical, Inc. (ISRG) reached $407.29 at the closing of the latest trading day, reflecting a +1.24% change compared to its last close.

Shares of Medtronic jumped 5% Wednesday after the medical-device maker reported better-than-expected quarterly results, helped by strong sales of devices used in heart procedures. The company also said it applied for U.

Intuitive Surgical falls 11% in a month despite strong revenues, procedure growth and da Vinci 5 adoption, raising questions about a potential rebound.

The medical device maker posts fiscal fourth-quarter earnings and revenue that narrowly beat analysts’ estimates.

Medtronic stock jumped Wednesday after the medical products giant said it requested new clearances for its robotic surgery system.

Intuitive Surgical is building an AI-driven surgical ecosystem, using da Vinci 5 data and connected workflows to deepen its robotic surgery moat.

A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow.

Don't wait too long to buy the dip on these stocks.

Intuitive Surgical (ISRG) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Despite recent underperformance relative to the healthcare sector, analysts remain fairly bullish on Intuitive Surgical's long-term fundamentals and growth potential.

This highly focused healthcare company has seen its shares fall 30% in 2026 despite still strong business growth.